LAM
REGN icon

Lummis Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Lummis Asset Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-5
Closed -$3.56K – 168
2024
Q4 		$3.56K Hold
5
– – ﹤0.01% 114
2024
Q3 		$5.26K Hold
5
– – 0.01% 110
2024
Q2 		$5.25K Hold
5
– – 0.01% 108
2024
Q1 		$4.81K Hold
5
– – 0.01% 115
2023
Q4 		$4.39K Buy
+5
New +$4.12K ﹤0.01% 139

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Lummis Asset Management's REGN Position: Q1 2025 in Review

Lummis Asset Management sold out of Regeneron Pharmaceuticals (REGN) in Q1 2025, closing a stake of 5 shares — an estimated $3.56K sold.

Lummis Asset Management first reported a position in REGN in Q4 2023 and held it in 5 quarters. The position peaked at $5.26K in Q3 2024. 1,290 funds tracked by Wall St. Rank hold REGN as of Q1 2025.

  • Lummis Asset Management reported no remaining Regeneron Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Lummis Asset Management sold 5 Regeneron Pharmaceuticals shares in Q1 2025, an estimated $3.56K.
  • Lummis Asset Management first reported a position in Regeneron Pharmaceuticals in Q4 2023 and held it in 5 quarters.
  • Lummis Asset Management's Regeneron Pharmaceuticals position peaked at $5.26K in Q3 2024.
  • 1,290 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2025.

Based on Lummis Asset Management's 13F filing for Q1 2025, filed 15 May 2025.